Trial reportLancet (London, England)2024
Trial report in Lancet (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 181 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.BJU international · 2026Guideline
- Liver Background Uptake of Prostate-specific Membrane Antigen-targeted PET Radiotracers: A Systematic Review and Meta-Analysis.Radiology. Imaging cancer · 2026Pooled it
- Prognostic factors of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Therapeutic outcomes of ²²⁵Ac/¹⁷⁷Lu-PSMA combination therapy in advanced metastatic Castration-Resistant prostate cancer: A systematic review and Meta-Analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Beyond [BMC cancer · 2026Pooled it
- Novel Therapeutic Strategies for Metastatic Prostate Cancer Care.European urology · 2025Pooled it
- Time for action: actinium-225 PSMA-targeted alpha therapy for metastatic prostate cancer - a systematic review and meta-analysis.Theranostics · 2025Pooled it
- Dosimetry Analysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- 131I-LNTH-1095 Radioligand Therapy plus Enzalutamide versus Enzalutamide Alone in Men with PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase II Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Phase 2 Prospective Trial of Retreatment with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Trial
- Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial.Signal transduction and targeted therapy · 2026Trial
- Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study.European journal of nuclear medicine and molecular imaging · 2026Trial
- Predictive value of early PSMA upregulation for the response to enzalutamide ±Nature cancer · 2026Trial
- Trial
- Final overall survival and safety analyses of the phase III PSMAfore trial of [Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Recent advances in PSMA therapy - from beta to alpha.Annals of nuclear medicine · 2026Review
- Radioligand therapy for pediatric patients with solid tumors.The British journal of radiology · 2026Review
- Clinical Trial Protocol for LPS-Boost: Intensified [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
121 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
24 authors.
Funding
Abstract
background[
methodsIn this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous
findingsOverall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive
interpretation
fundingNovartis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.